(VIANEWS) – The Market ended the session with MEDINCELL (MEDCL.PA) jumping 11.56% to €7.14 on Friday while CAC 40 jumped 0.75% to €7,315.07.
MEDINCELL’s last close was €6.40, 39.05% below its 52-week high of €10.50.
About MEDINCELL
MedinCell S.A. develops various therapeutic solutions in France. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension completed Phase III trial for use in the treatment of schizophrenia; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-TJK, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials, such as mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for use in organ transplant; mdc-WWM for contraception; mdc-STM for use in malaria; mdc-KPT for use in acute pain for pets; and mdc-IRM for use in neuroscience. The company was incorporated in 2003 and is based in Jacou, France.
Earnings Per Share
As for profitability, MEDINCELL has a trailing twelve months EPS of €-1.06.
Volatility
MEDINCELL’s last week, last month’s, and last quarter’s current intraday variation average was 0.40%, 0.12%, and 2.22%.
MEDINCELL’s highest amplitude of average volatility was 0.95% (last week), 1.22% (last month), and 2.22% (last quarter).
Yearly Top and Bottom Value
MEDINCELL’s stock is valued at €7.14 at 22:31 EST, way below its 52-week high of €10.50 and way above its 52-week low of €4.73.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MEDINCELL’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth grew by 77140%, now sitting on 9.89M for the twelve trailing months.
More news about MEDINCELL (MEDCL.PA).
